That is, although the body of data provides some evidence suggestive of a potential prognostic and predictive role of PD-L1 in MPM, it is possible that this results from heterogeneity in population characteristics (such as previous therapies received, lines of therapy received, disease subtype (epithelioid, sarcomatoid, or biphasic), stage, and performance status) and approaches to PD-L1 measurement (such as variations in PD-L1 assays and clones used, PD-L1 positivity cutpoint, cell type assessed [e.g., tumor cells versus immune cells], and time point assessed). This evidence concerns the gene CD274 and neoplasm.